# Pediatric Regulatory Pathway Navigator

**Niche:** [[niches/medical-device-mfg/pediatric-device-makers/profile|Pediatric Device Manufacturers]]
**Industry:** [[industries/medical-device-mfg|Medical Device Manufacturing]]
**Type:** Build (Greenfield Opportunity)
**One-liner:** No tool maps the pediatric-specific regulatory pathways (HDE, De Novo with pediatric subgroup analysis, 510(k) with pediatric predicate matching) and guides manufacturers through the evidence requirements unique to pediatric populations — forcing regulatory teams to navigate these uncommon pathways from scratch each time.
**Tags:** #large-language-models #text-generation #compliance #revenue-impact

## The Problem
A pediatric device manufacturer must choose between HDE (for devices treating fewer than 8,000 patients per year), De Novo (for novel devices without a predicate), and 510(k) (if a pediatric predicate exists) — each with different evidence requirements, review timelines, and post-market obligations. The HDE pathway requires demonstrating probable benefit without requiring effectiveness data, but the application format is unfamiliar to most regulatory affairs professionals who have only filed 510(k)s. Finding pediatric predicate devices in the FDA database is difficult because many pediatric devices are not labeled as such. Regulatory teams at small pediatric device companies (often 1-2 regulatory professionals) spend 3-6 months researching the optimal pathway before even beginning the submission.

## Why Nobody Has Built This
The market is small (fewer than 300 US companies focus primarily on pediatric devices). The regulatory pathways are complex and change as FDA issues new guidance. Building a pathway navigator requires deep domain expertise in both pediatric regulatory strategy and FDA database structure — a combination that exists in perhaps 50 people globally, none of whom work in software development.

## What to Build
An LLM-powered regulatory pathway advisor trained on FDA pediatric device guidance documents, HDE and De Novo review decisions, and pediatric predicate device data. It accepts a device description and intended pediatric population, recommends the optimal regulatory pathway with evidence requirements, identifies relevant pediatric predicates and precedent decisions, and generates a preliminary regulatory strategy document. Updated when FDA issues new pediatric guidance.

## Target Customer
VP Regulatory Affairs and regulatory consultants serving pediatric device companies. Approximately 200-300 US manufacturers plus 100+ regulatory consulting firms. Average contract value: $25-50K/year.

## Impact If Built
Regulatory pathway selection time drops from 3-6 months to 2-4 weeks. HDE and De Novo submission quality improves, reducing FDA review cycles by 1-2 rounds. More pediatric devices reach market — addressing a critical unmet clinical need.
